4.7 Article

Impact of Prolonged Exacerbation Recovery in Chronic Obstructive Pulmonary Disease

Journal

Publisher

AMER THORACIC SOC
DOI: 10.1164/rccm.201412-2269OC

Keywords

COPD; exacerbations; recovery; risk interval; nonrecovery

Funding

  1. Bartholomew's and the London NHS Trust
  2. University College London
  3. Royal Free Hospital
  4. National Institute of Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton Hospital
  5. Harefield Foundation NHS Trust
  6. Imperial College London
  7. National Institute for Health Research [NF-SI-0513-10077, NF-SI-0510-10270] Funding Source: researchfish

Ask authors/readers for more resources

Rationale: Exacerbations are important and heterogeneous events in the natural history of chronic obstructive pulmonary disease (COPD). Objectives: To examine the consequences of prolonged exacerbation recovery in patients with COPD. Methods: A cohort of 384 patients with COPD (FEV1 % predicted 45.8 [SD, 16.6] and a median exacerbation rate of 2.13 per year [interquartile range, 1.0-3.2]) were followed for 1,039 days (interquartile range, 660-1,814) between October 1995 and January 2013. Patients recorded daily worsening of respiratory symptoms and peak expiratory flow (PEF), and when stable underwent spirometry every 3 months, and completed the St. George's Respiratory Questionnaire annually. Exacerbations were diagnosed as 2 consecutive days with one major symptom plus another respiratory symptom. Exacerbation duration was defined as the time from onset to the day preceding 2 consecutive symptom-free days and recovery in PEF as return to preexacerbation levels. Measurements and Main Results: A total of 351 patients had one or more exacerbations. Patients with a longer symptom duration (mean, 14.5 d) had a worse St. George's Respiratory Questionnaire total score (0.2 units per 1 day; P = 0.040). A longer symptomatic duration was associated with a shorter interval between exacerbation recovery and onset of the next exacerbation (hazard ratio, 1.004; P = 0.013). For 257 (7.3%) exacerbations, PEF did not recover within 99 days. These exacerbations were associated with symptoms of a viral infection (cold and sore throat). Patients with these nonrecovered exacerbations showed a 10.8 ml/yr (P < 0.001) faster decline in FEV1. Conclusions: Prolonged exacerbation symptomatic duration is associated with poorer health status and a greater risk of a new event. Exacerbations where lung function does not recover are associated with symptoms of viral infections and accelerated decline in FEV1.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Critical Care Medicine

Inflammatory Endotype-associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations A Multicohort Longitudinal Analysis

Zhang Wang, Nicholas Locantore, Koirobi Haldar, Mohammadali Yavari Ramsheh, Augusta S. Beech, Wei Ma, James R. Brown, Ruth Tal-Singer, Michael R. Barer, Mona Bafadhel, Gavin C. Donaldson, Jadwiga A. Wedzicha, Dave Singh, Tom M. A. Wilkinson, Bruce E. Miller, Christopher E. Brightling

Summary: Analyzing the airway microbiome can help stratify neutrophilic COPD into subgroups that require different treatment approaches. Patients with neutrophilic COPD are susceptible to significant microbiome shifts during exacerbations, especially those in a stable state at baseline. Monitoring the temporal variability of the airway microbiome may provide insight into patient inflammatory status over time.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)

Article Critical Care Medicine

Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-Chronic Obstructive Pulmonary Disease Patients Time to Move Forward

Fernando J. Martinez, Alvar Agusti, Bartolome R. Celli, MeiLan K. Han, James P. Allinson, Surya P. Bhatt, Peter Calverley, Sanjay H. Chotirmall, Badrul Chowdhury, Patrick Darken, Carla A. Da Silva, Gavin Donaldson, Paul Dorinsky, Mark Dransfield, Rosa Faner, David M. Halpin, Paul Jones, Jerry A. Krishnan, Nicholas Locantore, Fernando D. Martinez, Hana Mullerova, David Price, Klaus F. Rabe, Colin Reisner, Dave Singh, Jorgen Vestbo, Claus F. Vogelmeier, Robert A. Wise, Ruth Tal-Singer, Jadwiga A. Wedzicha

Summary: Chronic obstructive pulmonary disease (COPD) is the result of gene-environment interactions. Therapeutic trials targeting young COPD patients and pre-COPD patients are proposed to slow down disease progression. This article provides a detailed approach for RCT design and outcome assessment, and emphasizes the need for treatment trials in young and pre-COPD patients.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)

Editorial Material Critical Care Medicine

Advancing Global Respiratory Health, Sleep, and Critical Care: Editorial from the New American Journal of Respiratory and Critical Care Medicine Team

Fernando J. Martinez, Laurent Brochard, Andrew Bush, Gavin Donaldson, MeiLan K. Han

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)

Article Respiratory System

Inhaled corticosteroids reduce senescence in endothelial progenitor cells from patients with COPD

Koralia Paschalaki, Christos Rossios, Charis Pericleous, Mairi MacLeod, Stephen Rothery, Gavin C. Donaldson, Jadwiga A. Wedzicha, Vassilis Gorgoulis, Anna M. Randi, Peter J. Barnes

Summary: Cellular senescence is accelerated in smokers and COPD patients. In COPD patients on inhaled corticosteroids, cellular senescence and DNA damage response are reduced. In vitro studies suggest that corticosteroids protect endothelial cells by reducing oxidative stress-induced senescence and apoptosis.

THORAX (2022)

Article Critical Care Medicine

Changes in lung function in European adults born between 1884 and 1996 and implications for the diagnosis of lung disease: a cross-sectional analysis of ten population-based studies

James P. Allinson, Shoaib Afzal, Yunus Colak, Debbie Jarvis, Helena Backman, Maarten van den Berge, H. Marike Boezen, Marie-Kathrin Breyer, Robab Breyer-Kohansal, Guy Brusselle, Otto C. Burghuber, Rosa Faner, Sylvia Hartl, Lies Lahousse, Arnulf Langhammer, Bo Lundback, Bright Nwaru, Eva Ronmark, Sigrid A. Aalberg Vikjord, Judith M. Vonk, Sara R. A. Wijnant, Peter Lange, Borge G. Nordestgaard, Nuria Olvera, Alvar Agusti, Gavin C. Donaldson, Jadwiga A. Wedzicha, Jorgen Vestbo, Lowie E. G. W. Vanfleteren

Summary: Socioeconomic and scientific advances have led to improvements in lung function among European populations, which may impact the interpretation of lung function measurements and the diagnosis of lung diseases. Analysis of cross-sectional data from ten European population-based studies revealed an increase in FEV1 and FVC values over the past century, while the FEV1/FVC ratio decreased.

LANCET RESPIRATORY MEDICINE (2022)

Editorial Material Critical Care Medicine

Obesity, Insulin Resistance, and Asthma

James P. Allinson, Pujan H. Patel, Gavin C. Donaldson

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)

Article Critical Care Medicine

Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study

Tessa M. Kole, Elise Vanden Berghe, Monica Kraft, Judith M. Vonk, Martijn C. Nawijn, Salman Siddiqui, Kai Sun, Leonardo M. Fabbri, Klaus F. Rabe, Kian Fan Chung, Gabriele Nicolini, Alberto Papi, Chris Brightling, Dave Singh, Thys van der Molen, Sven-Erik Dahlen, Alvar Agusti, Rosa Faner, Jadwiga A. Wedzicha, Gavin C. Donaldson, Ian M. Adcock, Lies Lahousse, Huib A. M. Kerstjens, Maarten van den Berge

Summary: This post-hoc analysis investigates the determinants, clinical implications, and outcome of persistent airflow limitation (PAL) in patients with asthma. The study reveals that PAL is not only present in severe asthma, but also in a considerable proportion of patients with milder disease. In patients with mild asthma, PAL is associated with eosinophilic inflammation and a higher risk of exacerbations, suggesting the need for increased treatment intensity.

LANCET RESPIRATORY MEDICINE (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

Dual-energy Computed Tomographic Pulmonary Angiography Accurately Estimates Lobar Perfusion Before Lung Volume Reduction for Severe Emphysema

Nidhish Jeyin, Sujal R. Desai, Simon P. G. Padley, Kshama Wechalekar, Sima Gregg, Tiago Sousa, Pallav L. Shah, James P. Allinson, Nicholas S. Hopkinson, Sofina Begum, Simon Jordan, Samuel V. Kemp, Carole A. Ridge

Summary: The purpose of this study was to evaluate whether dual-energy computed tomographic pulmonary angiography (DECTPA) derived lobar iodine quantification can accurately estimate lobar perfusion in patients with severe emphysema, and provide an adjunct to single-photon emission CT perfusion scintigraphy (SPECT-PS) in assessing suitability for lung volume reduction (LVR). The results showed that DECTPA provides an accurate estimation of lobar perfusion, showing good agreement with SPECT-PS, and could potentially streamline preoperative assessment for LVR.

JOURNAL OF THORACIC IMAGING (2023)

Article Critical Care Medicine

Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care

Pallav L. Shah, Christopher M. Orton, Beatriz Grinsztejn, Gavin C. Donaldson, Brenda Crabtree Ramirez, James Tonkin, Breno R. Santos, Sandra W. Cardoso, Andrew Ritchie, Francesca Conway, Maria P. D. Riberio, Dexter J. Wiseman, Anand Tana, Bavithra Vijayakumar, Cielito Caneja, Craig Leaper, Bobby Mann, Anda Samson, Pankaj K. Bhavsar, Marta Boffito, Mark R. Johnson, Anton Pozniak, Michael Pelly

Summary: This study evaluated the safety and efficacy of oral favipiravir in hospitalized patients with COVID-19. The results showed that although favipiravir did not improve clinical outcomes for all hospitalized patients, it might have a beneficial clinical response for patients younger than 60 years old. The indiscriminate use of favipiravir globally should be cautioned, and further high-quality studies of antiviral agents and treatment combinations are warranted in COVID-19.

LANCET RESPIRATORY MEDICINE (2023)

Editorial Material Critical Care Medicine

Exacerbations in Chronic Obstructive Pulmonary Disease: Clinical, Genetic, and Mycobiome Risk Factors

Kenki Matsumoto, Nicola Read, Keir E. J. Philip, James P. Allinson

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

Article Medicine, General & Internal

Early childhood lower respiratory tract infection and premature adult death from respiratory disease in Great Britain: a national birth cohort study

James Peter Allinson, Nishi Chaturvedi, Andrew Wong, Imran Shah, Gavin Christopher Donaldson, Jadwiga Anna Wedzicha, Rebecca Hardy

LANCET (2023)

Article Critical Care Medicine

A Double-Blind, Randomized, Placebo-controlled Trial of Long-Term Doxycycline Therapy on Exacerbation Rate in Patients with Stable Chronic Obstructive Pulmonary Disease

James P. Allinson, Ben H. Vlies, Simon E. Brill, Martin Law, Girvan Burnside, Lydia J. Finney, Luana Alves-Moreira, Gavin C. Donaldson, Peter M. A. Calverley, Paul P. Walker, Jadwiga A. Wedzicha

Summary: The study suggests that 12-month use of doxycycline did not significantly reduce the exacerbation rate in COPD patients, but it may be beneficial for those with severe COPD or high eosinophil counts.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

No Data Available